Evaxion Biotech A/S (EVAX)


-0.03 (-2.46%)
Symbol EVAX
Price $1.19
Beta 0.663
Volume Avg. 0.65M
Market Cap 31.442M
Shares () -
52 Week Range 0.97-3.52
1y Target Est -
DCF Unlevered EVAX DCF ->
DCF Levered EVAX LDCF ->
ROE -106.65% Strong Sell
ROA -89.88% Strong Sell
Operating Margin -
Debt / Equity 102.58% Buy
P/E -0.91
P/B 2.09 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest EVAX news

Dr. Niels Iversen Moeller M.D.
NASDAQ Capital Market

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.